Search research articles
Contact Us
Filters
Showing results (141-150 of 224) with videos related to
Page
of 23
Sort By:
Critical Reviews in Oncology/Hematology
|
September 10, 2022
Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors
Sara Elena Rebuzzi, Arsela Prelaj, Alex Friedlaender, et al.
Cancer
|
June 21, 2022
Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial
Alessio Cortellini, Biagio Ricciuti, Hossein Borghaei, et al.
Human Vaccines & Immunotherapeutics
|
May 18, 2021
Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma
Giulio Metro, Diego Signorelli, Elio G Pizzutilo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 6, 2026
Efficacy of Immune Checkpoint Inhibitors and Oncoviruses in Solid Tumors
Hiba Mechahougui, Léna Royston, Catia Vieira Gomes, et al.
Seminars in Oncology
|
April 15, 2025
Liquid biopsy: An innovative tool in oncology. Where do we stand?
Serafina Martella, Demi Wekking, Eleonora Lai, et al.
ESMO Open
|
June 26, 2020
ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer
Antonio Passaro, Alfredo Addeo, Christophe Von Garnier, et al.
American Journal of Clinical Oncology
|
June 7, 2007
Activity of weekly paclitaxel in advanced hormone-refractory prostate cancer
Isabella Chiappino, Paolo Destefanis, Alfredo Addeo, et al.
CA: a Cancer Journal for Clinicians
|
July 17, 2025
Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: Navigating early to advanced disease management
Maxime Borgeaud, Timothée Olivier, Jair Bar, et al.
Therapeutic Advances in Medical Oncology
|
February 17, 2022
Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC: a retrospective chart review (REFLECT)
Alfredo Addeo, Maximilian Hochmair, Urska Janzic, et al.
Translational Lung Cancer Research
|
September 21, 2020
Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab
Giuseppe Luigi Banna, Diego Signorelli, Giulio Metro, et al.
Page
of 23
Search research articles
Search
Showing results (141-150 of 224) with videos related to
Sort By:
Page
of 23
Critical Reviews in Oncology/Hematology
|
September 10, 2022
Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors
Sara Elena Rebuzzi, Arsela Prelaj, Alex Friedlaender, et al.
Cancer
|
June 21, 2022
Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial
Alessio Cortellini, Biagio Ricciuti, Hossein Borghaei, et al.
Human Vaccines & Immunotherapeutics
|
May 18, 2021
Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma
Giulio Metro, Diego Signorelli, Elio G Pizzutilo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 6, 2026
Efficacy of Immune Checkpoint Inhibitors and Oncoviruses in Solid Tumors
Hiba Mechahougui, Léna Royston, Catia Vieira Gomes, et al.
Seminars in Oncology
|
April 15, 2025
Liquid biopsy: An innovative tool in oncology. Where do we stand?
Serafina Martella, Demi Wekking, Eleonora Lai, et al.
ESMO Open
|
June 26, 2020
ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer
Antonio Passaro, Alfredo Addeo, Christophe Von Garnier, et al.
American Journal of Clinical Oncology
|
June 7, 2007
Activity of weekly paclitaxel in advanced hormone-refractory prostate cancer
Isabella Chiappino, Paolo Destefanis, Alfredo Addeo, et al.
CA: a Cancer Journal for Clinicians
|
July 17, 2025
Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: Navigating early to advanced disease management
Maxime Borgeaud, Timothée Olivier, Jair Bar, et al.
Therapeutic Advances in Medical Oncology
|
February 17, 2022
Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC: a retrospective chart review (REFLECT)
Alfredo Addeo, Maximilian Hochmair, Urska Janzic, et al.
Translational Lung Cancer Research
|
September 21, 2020
Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab
Giuseppe Luigi Banna, Diego Signorelli, Giulio Metro, et al.
Page
of 23